Category Archives: Myocardial Infarction

BMJ Open. Continue reading →

As a medical student, do you ever wonder what its like to specialize in interventional cardiology? Meet AMA member Elie Azrak, MD, an interventional cardiologist and a featured physician in the AMAs Shadow Me Specialty Series, which offers advice directly from physicians about life in their specialties Continue reading →

This article was originally published here Circulation. Continue reading →

This article was originally published here Ann Cardiol Angeiol (Paris). 2020 Nov 27:S0003-3928(20)30194-3. doi: 10.1016/j.ancard.2020.11.006 Continue reading →

This article was originally published here Anatol J Cardiol. 2020 Dec;24(6):364-369. doi: 10.14744/AnatolJCardiol.2020.98452. Continue reading →

Introduction Substantial evidence from randomized trials and observational studies suggests that high consumption of red meat, especially processed red meat, is associated with an increased risk of mortality123 and major chronic diseases,456789 including coronary heart disease (CHD).101112 Consequently, the 2015-20 US Dietary Guidelines for Americans13 encourage dietary patterns that are low in red and processed meat intake. Increases in risk were not, however, seen in Asian populations with low consumption of red meat, or in populations in which consumption of red meat has recently increased.141516 These inconsistencies could be due to the variable amounts and duration of red meat consumed in different populations,1516 inadequate differentiation between processed and unprocessed red meat,15171819 differences in the levels of controlling for confounding,1518 and, importantly, differences in the comparison sources of energy.15202122 In particular, in most populations, most energy intake come from refined starches, sugar, potatoes, and fats that are highly saturated or partially hydrogenated. Continue reading →

This article was originally published here Arch Med Res. Continue reading →

A chemotherapy-free combination regimen consisting of ibrutinib and rituximab (IR) produced high response rates and promising survival outcomes in previously untreated older patients with high-risk mantle cell lymphoma (MCL), according to results from a phase II trial presented at the 62nd American Society of Hematology Annual Meeting & Exposition. Continue reading →

This article was originally published here Cureus. 2020 Oct 29;12(10):e11247. doi: 10.7759/cureus.11247. Continue reading →

Eur Rev Med Pharmacol Sci. 2020 Nov;24(22):11690-11699. doi: 10.26355/eurrev_202011_23814 Continue reading →